Daniel Auclair Shares His List of ASH26 Abstracts

Daniel Auclair, President of Hematocure and Senior Vice President of Business Development at Predicta Biosciences, shared on X:

“It is this time of year again. Here is my list of ASH26 abstracts:

Phase 3 studies

1. Paper 114 Sagar Lonial et al EXCALIBER-RRMM. First pivotal Ph3 evaluation of MRD- CR alongside PFS as dual primary endpoint in RRMM.
2. Paper 274 Matthew Frigault et al. iMMagine-1; few ICANS and low grade, 24 mo PFS of 58%
3. Paper 424 Manier et al. In MagnetisMM-5 update, ELRA-DARA arm median PFS still not reached with 32.5 mo F/U and 36-mo PFS rate of 74.7%
4. Paper 426 Paula Rodriguez-Otero MonumenTAL-6 continues to underscore the benefit of targeting both BCMA and GPRC5D

The march of dual-targeting CAR and trispecifics

1. Paper 110 Marc S. Raab et al. Strong data for ramantamig in first line
2. Paper 116 Surbhi Sidana et al BMS-986453 dual BCMAxGPRC5D CAR: ORR of 94% for highest doses in this cohort with 60% BCMA exposed and 17% BCMA+GPRC5D exposed
3. Paper 269 Li et al, IBI3003 BCMAxGPRC5DxCD3 90.9% ORR in patients with prior BCMA, GPRC5D
4. Paper 421 Binod Dhakal TRIgnite-1 ISB2001 CD38xBCMAxCD3; 77% ORR in pts with prior BCMA CAR-T or TCE exposure
5. Paper 1054 Scott Goldsmith et al Early DURGA-2 trial data for AZD0120 CD19xBCMA CAR-T in HR NDMM

In vivo CARs at TCEs

1. Paper 266 Hans Lee et al Ph1 mRNA-2808 encoding multiplexed mRNA encoding BCMA, GPRC5D and FcRH5 TCEs
2. Paper 1051 Mei et al initial data for QI-019A CD19/BCMA dual targeting CAR

Blood-based residual disease monitoring

1. Paper 625 Gonzalez et al assessment of Peripheral Residual Disease (PRD) by BloodFlow continues to identify a group with very poor outcome Bruno Paiva
2. Paper 629 Mattia D’Agostino et al High NPV of PRD by mass spec to predict marrow MRD in IsKia. Paper 550 Novakova et al Real-world evaluation in NDMM and RRMM of CTC-based staging system

And finally a couple sentimental ones (I am conflicted here having  contributed to these)

1. Paper 1047 Perron et al Immune profiling in precursor conditions suggestive of MGUS and SMM as states of active, reversible immune collapse years before diagnosis Irene Ghobrial
2. Paper 5769 Matthew Pianko et al. Final analysis of MyDrug cobi-IPd arm in functional HR. From another era testing genomically-informed oral quads inspired from CoMMpass. Fond memories working on protocol and trial with Shaji Kumar and Hearn Jay Cho. The field since moved to immune therapies and genomics are now important in a different way to inform resistance to these new therapies.

Looking forward to great science and reconnecting in New Orleans!”

The 68th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH26) takes place from December 12 – 15, 2026, both in person in New Orleans, Louisiana, and virtually.  

ASH 2026 is the world’s largest annual gathering dedicated to blood diseases, bringing together over 30,000 doctors, researchers, and scientists to share new breakthroughs in diagnosing and treating blood cancers and inherited blood disorders.

Guided by the theme ‘Advancing Discovery, Transforming Care in Hematology,’ the event covers both cancerous (malignant) and non-cancerous (classical) blood conditions. Key focus areas include:

• Blood Cancers. Unveiling late-stage clinical trial data for leukemia, lymphoma, and multiple myeloma.
• Targeted and Cellular Therapies. Exploring advancements in CAR-T cell therapies, immunotherapies, and new targeted drugs.
• Classical Blood Disorders. Addressing clotting issues (thrombosis), sickle cell disease, anemia, and bone marrow failure.
• Emerging Tech and Diagnostics. Showcasing how artificial intelligence, genomic sequencing, and precision medicine are improving early detection and treatment planning. 

You can also read:

• Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026
• Talha Badar’s ASH 2026 Watchlist: 11 Key AML Studies